Department of Chinese Medicine Oncology, The First Affiliated Hospital of Naval Medical University, Shanghai 200433, China.
Department of Chinese Medicine, Naval Medical University, Shanghai 200433, China.
Nutrients. 2023 Sep 14;15(18):3984. doi: 10.3390/nu15183984.
Breast cancer (BC) is a lethal malignancy with high morbidity and mortality but lacks effective treatments thus far. Despite the introduction of immune checkpoint inhibitors (ICIs) (including PD-1/PD-L1 inhibitors), durable and optimal clinical benefits still remain elusive for a considerable number of BC patients. To break through such a dilemma, novel ICI-based combination therapy has been explored for enhancing the therapeutic effect. Recent evidence has just pointed out that the HDAC2 inhibitor (HDAC2i), which has been proven to exhibit an anti-cancer effect, can act as a sensitizer for ICIs therapy. Simultaneously, dietary intervention, as a crucial supportive therapy, has been reported to provide ingredients containing HDAC2 inhibitory activity. Thus, the novel integration of dietary intervention with ICIs therapy may offer promising possibilities for improving treatment outcomes. In this study, we first conducted the differential expression and prognostic analyses of HDAC2 and BC patients using the GENT2 and Kaplan-Meier plotter platform. Then, we summarized the potential diet candidates for such an integrated therapeutic strategy. This article not only provides a whole new therapeutic strategy for an HDAC2i-containing diet combined with PD-1/PD-L1 inhibitors for BC treatment, but also aims to ignite enthusiasm for exploring this field.
乳腺癌（BC）是一种致命的恶性肿瘤，发病率和死亡率都很高，但到目前为止还缺乏有效的治疗方法。尽管免疫检查点抑制剂（ICIs）（包括 PD-1/PD-L1 抑制剂）的引入，相当数量的 BC 患者仍然难以获得持久和最佳的临床获益。为了突破这一困境，人们探索了基于新型 ICI 的联合治疗方法，以增强治疗效果。最近的证据表明，已经被证明具有抗癌作用的 HDAC2 抑制剂（HDAC2i）可以作为 ICI 治疗的增敏剂。同时，饮食干预作为一种重要的支持性治疗方法，已被报道提供含有 HDAC2 抑制活性的成分。因此，将饮食干预与 ICI 治疗相结合可能为改善治疗效果提供有前途的可能性。在这项研究中，我们首先使用 GENT2 和 Kaplan-Meier plotter 平台对 HDAC2 和 BC 患者进行了差异表达和预后分析。然后，我们总结了这种综合治疗策略的潜在饮食候选物。本文不仅为含有 HDAC2i 的饮食与 PD-1/PD-L1 抑制剂联合治疗 BC 提供了全新的治疗策略，还旨在激发人们对该领域的探索热情。
